Hope, healing, and happy endings — real stories from international families who trusted Jingdu Children's Hospital with their children's care.
Pediatric Leukemia — HSCT
When an 8-year-old boy from Southeast Asia experienced a second relapse of acute lymphoblastic leukemia, his local doctors said there were no further treatment options. The family had exhausted all available therapies in their home country, and the prognosis seemed dire.
Desperate for a solution, the family reached out to Beijing Jingdu Children's Hospital. After a remote consultation and review of the child's complete medical history, Professor Wu Nanhai's hematology team developed an innovative treatment protocol combining salvage chemotherapy with a haploidentical stem cell transplant using the child's mother as the donor.
The family traveled to Beijing, where the child underwent the comprehensive treatment program in our international inpatient department. The haploidentical transplant was successful, and after a period of careful post-transplant monitoring, the child achieved complete remission. Today, the child is back home, attending school, and thriving — with regular remote follow-up consultations ensuring continued health.
"The team at Jingdu Children's gave our son a second chance when no one else could. We will be forever grateful."
— The patient's mother
A 5-year-old child from an African nation was born with a complex congenital heart defect — tetralogy of Fallot — that required specialized surgical intervention unavailable in their home country. The child suffered from cyanotic spells, fatigue, and failure to thrive, with each passing month bringing more urgency.
An international medical charity connected the family with Beijing Jingdu Children's Hospital. After reviewing the child's echocardiogram and cardiac imaging remotely, Professor Liu Yinglong's cardiac surgery team confirmed that surgical correction was possible with excellent long-term prognosis.
The family traveled to Beijing, where Prof. Liu performed a complete surgical repair of the tetralogy of Fallot using advanced techniques. The child's recovery in our pediatric cardiac ICU was smooth and complication-free. Within weeks, the child's oxygen levels normalized, energy returned, and for the first time, the child could run and play without turning blue. The family returned home with a healthy, active child and regular telemedicine follow-ups to monitor cardiac function.
"We arrived with a sick child who couldn't walk ten steps. We left with a little boy who runs and laughs. Professor Liu gave our son his childhood back."
— The patient's father
Congenital Heart Disease — Tetralogy of Fallot Repair
Pompe Disease — Gene Testing & Enzyme Replacement Therapy
A 3-year-old child from a European country presented with progressive muscle weakness, delayed motor development, and respiratory difficulties. Despite multiple consultations with specialists at home, a definitive diagnosis remained elusive for over a year. The family was told the condition might be a rare genetic disorder, but local facilities lacked the capability for comprehensive genetic testing.
The family contacted Jingdu Children's Hospital seeking answers. Through our Rare Disease MDT Center and 800m² central laboratory, advanced gene sequencing was performed using the child's blood samples sent via international courier. The results confirmed a diagnosis of Pompe disease, a rare and progressive neuromuscular disorder caused by acid alpha-glucosidase (GAA) enzyme deficiency.
The family traveled to Beijing, where our multidisciplinary team initiated enzyme replacement therapy (ERT) — the standard-of-care treatment for Pompe disease. Our specialists worked closely with the child's home physicians to coordinate long-term treatment, and regular remote follow-ups monitor the child's progress. The child has shown significant improvement in muscle strength and motor function, with continued ERT administration coordinated through the family's local healthcare system.
"For over a year, we didn't know what was wrong with our child. Jingdu Children's gave us a diagnosis, a treatment plan, and most importantly — hope."
— The patient's parents
A 6-year-old child was diagnosed with primary hemophagocytic lymphohistiocytosis (HLH), a life-threatening immune disorder. The family, from a country with limited access to specialized pediatric transplant services, faced an urgent situation — without a stem cell transplant, HLH has a very poor prognosis, and time was critical.
The family reached out to Jingdu Children's Hospital after learning about our status as Asia's largest pediatric HSCT center. Due to the urgency of the condition, our team expedited the remote consultation process, and within days confirmed that a haploidentical transplant using the child's father as donor was feasible.
The child underwent a modified haploidentical HSCT using the groundbreaking protocol developed by Professor Wu Minyuan's team — the same protocol that achieved a 78.4% 2-year survival rate and 73.7% 5-year survival rate for primary HLH. The transplant was successful, and after the engraftment and recovery period, the child's immune system was restored. Today, the child lives free from HLH, with ongoing remote monitoring confirming sustained remission and normal immune function.
"HLH is a race against time, and the team at Jingdu Children's understood that. They acted fast, and I was able to be the donor for my own child. Today my daughter is healthy and happy."
— The patient's father (donor)
Primary HLH — Haploidentical HSCT
Families from over 100 countries have chosen Jingdu Children's for pediatric care.
Internationally trained pediatric specialists with decades of experience in complex cases.
World-class treatment at costs 50-70% lower than Western countries, with full transparency.
Ongoing remote follow-up and coordination with your home physician after treatment.